Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Hemochromatosis by Phase

  • There are currently 6 ongoing clinical trials involving Hemochromatosis

  • Of the 6 trials,3 trials are in Phase II

  • Furthermore, 2 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Hemochromatosis by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Hemochromatosis, a genetic disorder. The largest number of ongoing clinical trials for Hemochromatosis is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Hemochromatosis-related drug trials.

Hemochromatosis related clinical trial sponsor

Protagonist Therapeutics Inc, Jichi Medical University, Kagoshima City Hospital, Novartis AGVifor Pharma Ltd, National Center for Child Health and Development, Kanazawa University Hospital, AND University Health Network are among other notable clinical trial sponsors involved in Hemochromatosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hemochromatosis

Deferoxamine mesylate (Desferal), Deferasirox, and Deferasirox ODT (Deferasirox) are among the key marketed drugs involving Hemochromatosis.

Deferoxamine mesylate (Desferal) is an iron-chelating agent. It functions via Iron Chelator mechanism of action. It is formulated as injection for intravenous, intramuscular or subcutaneous route of administration. Deferoxamine mesylate is marketed for the treatment of Hemochromatosis and several other indications including Thalassemia, Acquired (Autoimmune) Hemolytic Anemia, and Iron Poisoning. Deferoxamine mesylate was first approved in 1963 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Novartis AG and its subsidiaries.

Deferasirox is an iron chelating agent. It functions via Iron Chelator mechanism of action. It is formulated as tablets for oral route of administration. Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. Deferasirox was first approved in 2019 and is marketed in the US by Piramal Healthcare UK Ltd.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward